A combination of Xeloda and Eloxatin (XELOX) was better than standard 5-FU and leucovorin chemotherapy in reducing recurrences of stage III colon cancer after surgery. Significantly more patients receiving XELOX were alive without cancer three years after treatment began.
Roche announced results of a Phase III clinical trial that compared XELOX chemotherapy to bolus 5-FU and leucovorin. The trial, nicknamed XELOXA (NO16968), enrolled almost 1,900 patients in 29 countries.
Its primary goal was to see if combining the oral drug Xeloda® (capecitabine) with Eloxatin® (oxaliplatin) could improve disease-free survival for stage III colon cancer patients. Read the rest of this entry »